Trial Profile
A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Aug 2019
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Luye Pharma Group
- 16 Apr 2018 New trial record